

[Chem. Pharm. Bull.]  
36(7)2665—2668(1988)

## Quinolizidines. XXIV.<sup>1)</sup> Syntheses of Ankorine Congeners in Different Oxidation States

TOZO FUJII\* and MASASHI OHBA


Faculty of Pharmaceutical Sciences, Kanazawa University,  
Takara-machi, Kanazawa 920, Japan

(Received February 1, 1988)

8-Hydroxyprotoemetine [(−)-**2f**], an aldehyde of biogenetic interest, has been synthesized for the first time from the tricyclic ester (−)-**5** through the intermediate (−)-**6**. Wolff–Kishner reduction of (−)-**2f** produced the 2-ethyl congener (−)-**2g**. As a result of these syntheses, the circular dichroism (CD) spectra of (−)-**2f**·HClO<sub>4</sub> and (−)-**2g** in 0.1 N aqueous HCl and in EtOH, together with those of the *Alangium* alkaloids ankorine (**2d**) and alancine (**2e**), are now available.

**Keywords**—hydroxyprotoemetine; deoxyankorine; benzyl ether hydrogenolysis; diisobutyl-aluminum hydride ester reduction; Wolff–Kishner reduction; *Alangium* alkaloid CD

Nineteen benzo[*a*]quinolizidine alkaloids isolated so far from *Alangium* plants (Alangiaceae) are structurally classified into four types (1–4) (R = CH<sub>2</sub>OH, CO<sub>2</sub>H, or a heterocyclic ring)<sup>2)</sup> according to their substitution patterns in the aromatic ring A.<sup>3,4)</sup> Type 2 includes four alkaloids, alangicine (**2b**),<sup>1,5)</sup> alangimarckine (**2c**),<sup>1,6)</sup> ankorine (**2d**),<sup>1,6a,7)</sup> and alancine (**2e**),<sup>1,8)</sup> all isolated from *A. lamarckii*. Interestingly, the latter two bases are



equivalent to the aldehydic base **2f** which has not been isolated yet from the same plant. On the other hand, protoemetine (**1f**), the corresponding tricyclic aldehyde of 1-type, was actually isolated from *Cephaelis ipecacuanha* (Rubiaceae),<sup>3c,9)</sup> and its probable intermediacy has been assumed in the biogenetic transformation of the precursor deacetylisopecoside into other ipecac alkaloids such as cephaeline (**1a**: 6'-OMe replaced by OH) and emetine (**1a**).<sup>3a,10,11)</sup> It is, therefore, not unreasonable to postulate 8-hydroxyprotoemetine (**2f**) to be a possible intermediate for the biosynthesis of the 2-type alkaloids **2b–e** in *A. lamarckii*. The availability of synthetic reference samples would greatly facilitate the search for this aldehyde




Chart 1

as a natural product and the testing of this speculation. Furthermore, the availability of the 2-ethyl analogue **2g** should complete a series of ankorine congeners (**2d–g**) differing in oxidation state at the side chain. This led us to synthesize **2f** and **2g** for the first time in the present work.

The first target selected for synthesis was 8-hydroxyprotoemetine (**2f**), the desired tricyclic aldehyde, which was expected to be accessible from the known tricyclic ester **(-)-5**, a common key intermediate utilized in our previous syntheses of ankorine (**2d**),<sup>1,7c,f)</sup> alangicine (**2b**),<sup>1,5c,d)</sup> alangimarckine (**2c**),<sup>1,6c,d)</sup> and alancine (**2e**).<sup>1,8b,c)</sup> Thus, debenzoylation of **(-)-5** was effected in EtOH by using hydrogen and 10% Pd-C catalyst at 24 °C for 1 h, giving the phenolic base **(-)-6** in 96% yield. On reduction with diisobutylaluminum hydride in  $\text{CH}_2\text{Cl}_2$ -hexane at  $-78^\circ\text{C}$ , **(-)-6** afforded the desired aldehyde **(-)-2f** in 85% yield. The aldehyde was unstable as the free base, but formed a crystalline perchlorate [**(-)-2f·HClO<sub>4</sub>**] in 91% yield when treated with aqueous  $\text{HClO}_4$ . For the synthesis of the second target structure **2g**, Wolff-Kishner reduction of **(-)-2f** was then carried out by means of the Huang-Minlon modification to give the deoxyankorine **(-)-2g** in 80% yield.

Now that all four functional members in the ankorine series had become available, it was possible to measure their circular dichroism (CD) spectra. It may be seen from Fig. 1 that **2d**,<sup>7c,f)</sup> **2e**,<sup>8b,c)</sup> **(-)-2f·HClO<sub>4</sub>**, and **(-)-2g** showed similar CD curves in 0.1 N aqueous HCl with the exception that the curve of **(-)-2f·HClO<sub>4</sub>** has an additional shoulder at 300 nm. In EtOH (Fig. 2), however, the free base **(-)-2g** exhibited a CD curve similar to that reported<sup>8c)</sup> for ankorine (**2d**), and those of the salts **2e·HCl**<sup>8b,c)</sup> and **(-)-2f·HClO<sub>4</sub>** were similar to each other, but different from that of the free base **(-)-2g** or **2d**. Interestingly, the shape of the CD curve of alancine (**2e**) in EtOH suggests the presence of the dipolar ion form (**7**) in a certain proportion in ethanolic solution. The existence of this dipolar ion form in the solid state has already been demonstrated by infrared (IR) spectroscopy.<sup>8c)</sup>

With the completion of the above syntheses and characterization of the hydroxyprotoemetine **(-)-2f** and the deoxyankorine **(-)-2g**, the search for these substances in plants will be facilitated.




Fig. 1. CD Curves of Ankorine (**2d**) and Its Congeners in 0.1 N Aqueous HCl

-----: **2d** ( $c = 4.66 \times 10^{-4}$  M) at 22°C. —: **2e** ( $c = 4.68 \times 10^{-4}$  M) at 20°C. ....: (–)-**2f**·HClO<sub>4</sub> ( $c = 4.70 \times 10^{-4}$  M) at 22°C. - · - ·: (–)-**2g** ( $c = 4.70 \times 10^{-4}$  M) at 20°C.




Fig. 2. CD Curves of Alancine (**2e**) and Its Congeners in 99% Aqueous EtOH

—: **2e** ( $c = 2.65 \times 10^{-4}$  M) at 20°C. -----: **2e**·HCl ( $c = 4.13 \times 10^{-4}$  M) at 22°C. ....: (–)-**2f**·HClO<sub>4</sub> ( $c = 4.05 \times 10^{-4}$  M) at 20°C. - · - ·: (–)-**2g** ( $c = 3.10 \times 10^{-4}$  M) at 20°C.

### Experimental

**General Notes**—All melting points were determined by using a Yamato MP-1 capillary melting point apparatus and are corrected. See ref. 8c for details of instrumentation and measurements. Elemental analyses were performed by Mr. Y. Itatani and his associates at Kanazawa University. The following abbreviations are used: br = broad, dd = doublet-of-doublets, q = quartet, s = singlet, t = triplet.

**(2R,3R,11bS)-3-Ethyl-1,3,4,6,7,11b-hexahydro-8-hydroxy-9,10-dimethoxy-2H-benzo[*a*]quinolizidine-2-acetic Acid Ethyl Ester [(–)-**6**]**—A solution of (–)-**5**<sup>1,7c,f</sup> (561 mg, 1.2 mmol) in EtOH (20 ml) was hydrogenated over 10% Pd/C (200 mg) at ordinary pressure and 24°C for 1 h. The catalyst was removed by filtration, and the filtrate was concentrated *in vacuo* to leave a yellow oil. Purification of the oil by means of flash chromatography<sup>12)</sup> [Silica gel 60 (E. Merck, No. 9385), AcOEt–hexane (1 : 1, v/v)] afforded (–)-**6** (433 mg, 96%) as a faintly yellowish oil,  $[\alpha]_D^{20} - 35.6^\circ$  ( $c = 0.50$ , EtOH); MS  $m/z$ : 377 ( $M^+$ ); IR  $\nu_{\text{max}}^{\text{CHCl}_3}$  cm<sup>–1</sup>: 3540 (OH), 2810, 2760 (*trans*-quinolizidine ring),<sup>13)</sup> 1727 (ester CO); NMR (CDCl<sub>3</sub>)  $\delta$ : 0.91 (3H, t,  $J = 6.5$  Hz, CCH<sub>2</sub>Me), 1.28 (3H, t,  $J = 7$  Hz, OCH<sub>2</sub>Me), 3.81 and 3.86 (3H each, s, two OMe's), 4.17 (2H, q,  $J = 7$  Hz, OCH<sub>2</sub>Me), 5.80 (1H, s, OH), 6.28 [1H, s, H(11)].

**(2R,3R,11bS)-3-Ethyl-1,3,4,6,7,11b-hexahydro-8-hydroxy-9,10-dimethoxy-2H-benzo[*a*]quinolizidine-2-acetaldehyde (8-Hydroxyprotoemetine) [(–)-**2f**]**—A stirred solution of (–)-**6** (403 mg, 1.07 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (12 ml) was cooled to –78°C in an atmosphere of N<sub>2</sub>, and a 1.0 M solution (2.4 ml, 2.4 mmol) of diisobutylaluminum hydride in hexane was added dropwise over 15 min. After the mixture had been stirred at –78°C for 1 h, the reaction was quenched by adding MeOH (0.5 ml). The resulting mixture, after addition of 10% aqueous Rochelle salt (10 ml), was stirred at 0°C for 30 min. Then, the pH of the aqueous layer was adjusted to ca. 7 with 10% aqueous HCl. The CH<sub>2</sub>Cl<sub>2</sub> layer was separated from the aqueous layer, which was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined CH<sub>2</sub>Cl<sub>2</sub> extracts were washed with saturated aqueous NaCl, dried over anhydrous MgSO<sub>4</sub>, and concentrated *in vacuo* to leave a yellow glass. The glass was purified by means of flash chromatography<sup>12)</sup> [Silica gel 60 (E. Merck, No. 9385), AcOEt–hexane (3 : 1, v/v)] to give (–)-**2f** (302 mg, 85%) as a pale yellow, unstable glass,  $[\alpha]_D^{18} - 42.9^\circ$  ( $c = 0.50$ , CHCl<sub>3</sub>)<sup>14)</sup>; MS  $m/z$ : 333 ( $M^+$ ); IR  $\nu_{\text{max}}^{\text{CHCl}_3}$  cm<sup>–1</sup>: 3540 (OH), 2810, 2760 (*trans*-quinolizidine ring),<sup>13)</sup> 1724 (aldehyde CO); NMR (CDCl<sub>3</sub>)  $\delta$ : 0.92 (3H, dull t,  $J = 6.5$  Hz, CCH<sub>2</sub>Me), 3.82 and 3.86 (3H each, s, two OMe's), 5.81 (1H, br, OH), 6.27 [1H, s, H(11)], 9.87 (1H, dd,  $J = 2, 1.5$  Hz, CHO).

**(2R,3R,11bS)-3-Ethyl-1,3,4,6,7,11b-hexahydro-8-hydroxy-9,10-dimethoxy-2H-benzo[*a*]quinolizidine-2-acetaldehyde Perchlorate (8-Hydroxyprotoemetine Perchlorate) [(–)-**2f**·HClO<sub>4</sub>]**—A solution of 70% aqueous HClO<sub>4</sub> (89 mg, 0.62 mmol) in H<sub>2</sub>O (1 ml) was added to an ice-cooled solution of (–)-**2f** (207 mg, 0.62 mmol) in EtOH (1 ml). The mixture was then concentrated *in vacuo* to a volume of ca. 1 ml, and the precipitate that resulted was filtered off, washed with H<sub>2</sub>O, and dried to give (–)-**2f**·HClO<sub>4</sub>·H<sub>2</sub>O (254 mg, 91%). Recrystallization from H<sub>2</sub>O–EtOH (8 : 1, v/v) and drying over P<sub>2</sub>O<sub>5</sub> at 2 mmHg and 100°C for 4 h furnished an analytical sample as colorless minute needles,

mp 216—217 °C;  $[\alpha]_D^{25} -23.0^\circ$  [ $c=0.50$ , 70% (v/v) aqueous EtOH]; CD (Figs. 1 and 2); IR  $\nu_{\max}^{\text{Nujol}} \text{ cm}^{-1}$ : 3550, 3480 (OH, H<sub>2</sub>O), 1726 (aldehyde CO); NMR (Me<sub>2</sub>SO-*d*<sub>6</sub>)  $\delta$ : 0.86 (3H, t,  $J=7$  Hz, CCH<sub>2</sub>Me), 3.67 and 3.77 (3H each, s, two OMe's), 4.37 [1H, dull t,  $J=9.5$  Hz, H(11b)], 6.43 [1H, s, H(11)], 9.25 (1H, s, OH or N<sup>+</sup>H), 9.4 (1H, br, N<sup>+</sup>H or OH), 9.77 (1H, s, CHO). *Anal.* Calcd for C<sub>19</sub>H<sub>28</sub>ClNO<sub>8</sub>·H<sub>2</sub>O: C, 50.50; H, 6.69; N, 3.10. Found: C, 50.71; H, 6.40; N, 2.98.

**(2R,3R,11bS)-2,3-Diethyl-1,3,4,6,7,11b-hexahydro-8-hydroxy-9,10-dimethoxy-2H-benzo[*a*]quinolizine [(–)-2g]**  
—A stirred mixture of (–)-2f (123 mg, 0.37 mmol), ethylene glycol (1 ml), 80% aqueous hydrazine hydrate (50 mg, 0.80 mmol), and KOH (75 mg) was heated under N<sub>2</sub> in an oil bath kept at 120 °C for 1 h. Then, the temperature of the oil bath was slowly raised to 190 °C in 30 min, and the mixture was further heated at 190—195 °C with stirring for 3 h. After cooling, the reaction mixture was poured into H<sub>2</sub>O (5 ml), and the resulting solution was neutralized with 10% aqueous HCl and then extracted with CHCl<sub>3</sub>. The CHCl<sub>3</sub> extracts were washed with saturated aqueous NaCl, dried over anhydrous MgSO<sub>4</sub>, and concentrated *in vacuo* to leave a brown glass. Purification of the glass was carried out by flash chromatography<sup>12)</sup> [Silica gel 60 (E. Merck, No. 9385), AcOEt–hexane (1 : 2, v/v)] to afford (–)-2g (94 mg, 80%) as a colorless solid, mp 107—108 °C. Recrystallization from hexane yielded an analytical sample as colorless scales, mp 108—108.5 °C;  $[\alpha]_D^{20} -79.5^\circ$  ( $c=0.51$ , EtOH); MS  $m/z$ : 319 (M<sup>+</sup>); CD (Figs. 1 and 2); IR  $\nu_{\max}^{\text{CHCl}_3} \text{ cm}^{-1}$ : 3550 (OH), 2815, 2760 (*trans*-quinolizidine ring);<sup>13)</sup> NMR (CDCl<sub>3</sub>)  $\delta$ : 0.91 (6H, t,  $J=6.5$  Hz, two CCH<sub>2</sub>Me's), 3.85 and 3.87 (3H each, s, two OMe's), 5.78 (1H, s, OH), 6.34 [1H, s, H(11)]. *Anal.* Calcd for C<sub>19</sub>H<sub>29</sub>NO<sub>3</sub>: C, 71.44; H, 9.15; N, 4.38. Found: C, 71.30; H, 9.28; N, 4.39.

**Acknowledgment** This work was supported by a Grant-in-Aid for Scientific Research (No. 61570997) from the Ministry of Education, Science and Culture, Japan.

#### References and Notes

- 1) Paper XXIII in this series, T. Fujii, M. Ohba, K. Shimohata, and S. Yoshifuji, *Heterocycles*, **26**, 2949 (1987).
- 2) Unless otherwise noted, the structural formulas of optically active compounds in this paper represent their absolute configurations.
- 3) For recent reviews on the *Alangium* alkaloids, see a) T. Fujii and M. Ohba, "The Alkaloids," Vol. XXII, ed. by A. Brossi, Academic Press, New York, 1983, Chapter 1; b) T. Fujii, *Yakugaku Zasshi*, **103**, 257 (1983); c) W. Wiegrebbe, W. J. Kramer, and M. Shamma, *J. Nat. Prod.*, **47**, 397 (1984); e) T. Fujii, M. Ohba, and S. Yoshifuji, *Heterocycles*, **27**, 1009 (1988).
- 4) This classification was first proposed by us in a previous paper: T. Fujii, M. Ohba, and H. Suzuki, *Chem. Pharm. Bull.*, **33**, 1023 (1985).
- 5) a) S. C. Pakrashi and E. Ali, *Tetrahedron Lett.*, **1967**, 2143; b) T. Fujii, K. Yamada, S. Yoshifuji, S. C. Pakrashi, and E. Ali, *ibid.*, **1976**, 2553; c) T. Fujii, S. Yoshifuji, S. Minami, S. C. Pakrashi, and E. Ali, *Heterocycles*, **8**, 175 (1977); d) T. Fujii, K. Yamada, S. Minami, S. Yoshifuji, and M. Ohba, *Chem. Pharm. Bull.*, **31**, 2583 (1983).
- 6) a) A. R. Battersby, R. S. Kapil, D. S. Bhakuni, S. P. Popli, J. R. Merchant, and S. S. Salgar, *Tetrahedron Lett.*, **1966**, 4965; b) T. Fujii, S. Yoshifuji, and H. Kogen, *ibid.*, **1977**, 3477; c) T. Fujii, H. Kogen, and M. Ohba, *ibid.*, **1978**, 3111; d) T. Fujii, H. Kogen, S. Yoshifuji, and M. Ohba, *Chem. Pharm. Bull.*, **33**, 1946 (1985).
- 7) a) B. Dasgupta, *J. Pharm. Sci.*, **54**, 481 (1965); b) T. Fujii, S. Yoshifuji, and K. Yamada, *Tetrahedron Lett.*, **1975**, 1527; c) S. Yoshifuji and T. Fujii, *ibid.*, **1975**, 1965; d) C. Szántay, E. Szentirmay, L. Szabó, and J. Tamás, *Chem. Ber.*, **109**, 2420 (1976); e) T. Fujii, S. Yoshifuji, and K. Yamada, *Tetrahedron*, **36**, 965 (1980); f) T. Fujii and S. Yoshifuji, *J. Org. Chem.*, **45**, 1889 (1980); g) T. Fujii, M. Ohba, and S. Akiyama, *Chem. Pharm. Bull.*, **33**, 1716 (1985); h) *Idem*, *ibid.*, **33**, 5316 (1985); i) T. Fujii, M. Ohba, K. Yoneyama, H. Kizu, and S. Yoshifuji, *ibid.*, **34**, 669 (1986).
- 8) a) S. K. Chattopadhyay, D. J. Slatkin, P. L. Schiff, Jr., and A. B. Ray, *Heterocycles*, **22**, 1965 (1984); b) T. Fujii, M. Ohba, A. Yonezawa, J. Sakaguchi, S. K. Chattopadhyay, D. J. Slatkin, P. L. Schiff, Jr., and A. B. Ray, *ibid.*, **24**, 345 (1986); c) T. Fujii, M. Ohba, A. Yonezawa, and J. Sakaguchi, *Chem. Pharm. Bull.*, **35**, 3470 (1987).
- 9) a) A. R. Battersby, G. C. Davidson, and B. J. T. Harper, *J. Chem. Soc.*, **1959**, 1744; b) A. R. Battersby and B. J. T. Harper, *ibid.*, **1959**, 1748.
- 10) a) N. Nagakura, G. Höfle, and M. H. Zenk, *J. Chem. Soc., Chem. Commun.*, **1978**, 896; b) N. Nagakura, G. Höfle, D. Coggiola, and M. H. Zenk, *Planta Med.*, **34**, 381 (1978).
- 11) A. R. Battersby, N. G. Lewis, and J. M. Tippet, *Tetrahedron Lett.*, **1978**, 4849.
- 12) W. C. Still, M. Kahn, and A. Mitra, *J. Org. Chem.*, **43**, 2923 (1978).
- 13) a) F. Bohlmann, *Chem. Ber.*, **91**, 2157 (1958); b) E. Wenkert and D. K. Roychaudhuri, *J. Am. Chem. Soc.*, **78**, 6417 (1956).
- 14) In 99% aqueous EtOH, this material slowly changed its optical rotation (levorotatory) during measurement at 23 °C. This precluded us from recording the specific rotation in EtOH.